STOCK TITAN

Numinus Wellness Inc. - $NUMIF STOCK NEWS

Welcome to our dedicated page for Numinus Wellness news (Ticker: $NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Numinus Wellness's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Numinus Wellness's position in the market.

Rhea-AI Summary

Numinus Wellness Inc. announces a strategic plan to focus on U.S. operations for higher growth and profitability. The company is enhancing its wellness clinics and clinical research facilities, launching a membership program for healthcare professionals in psychedelic-assisted therapies, and collaborating with Field Trip Health. Numinus also entered into an agreement with Field Trip Health to transition Canadian clinic operations, aiming to optimize therapy and training expertise while maximizing shareholder returns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
none
-
Rhea-AI Summary
Numinus Wellness Inc. announces Cedar Clinical Research as a site for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder. In Phase 2, 75% of patients achieved remission from depression symptoms. The FDA granted CYB003 breakthrough therapy designation. Phase 3 enrollment starts mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.27%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. provides a corporate update focusing on streamlining operations, maximizing shareholder returns, expanding Psychedelic Assisted Therapy training, and exploring opportunities to redefine, divest, or discontinue Canadian clinical operations. The company sharpens its focus on growth opportunities in the U.S. while maintaining support for Canadian organizations and healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
none
Rhea-AI Summary
Numinus Wellness Inc. reported Q2 Fiscal 2024 results with a cash position of $6.6 million, a gross profit of $0.5 million, and revenue of $5.0 million. The company doubled enrolment in training programs, managed 15 clinical trials, and provided 17,661 client appointments. Numinus submitted a Clinical Trial Application to Health Canada for MDMA-assisted psychotherapy. Despite revenue and gross margin declines, the company focused on profitability and cost containment measures. Operational highlights include revenue decline in wellness clinics, clinical research revenues, and clinical training program success. Corporate updates included key appointments and retirements. Numinus ended the quarter with $6.6 million in cash and a positive outlook for growth in the psychedelic sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. to release financial results for Q2 2024 on April 15, 2024. The company focuses on psychedelic-assisted therapies for mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences earnings
-
Rhea-AI Summary
Numinus Wellness Inc. submits a Clinical Trial Application to Health Canada for a group model in MDMA-assisted psychotherapy, focusing on practitioner training and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.54%
Tags
Rhea-AI Summary
Numinus Wellness Inc. announces the new date for its Annual General Meeting, along with the appointment of directors and an interim Chief Financial Officer. The company is focused on mental health care and innovative behavioral health treatments, with a strong emphasis on evidence-based therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
none
-
Rhea-AI Summary
Numinus Wellness Inc. congratulates Mind Medicine on positive data from Phase 2b clinical trial of MM120 for GAD, showing significant improvement in anxiety treatment. FDA designates MM120 as a breakthrough therapy for GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
-
Rhea-AI Summary
Numinus Wellness Inc. announced its Q1 2024 financial results, reporting a gross profit of $2.1 million, a 18.8% increase over Q4 2023, and a revenue decline of 3.0%. The company reduced operating expenditures by 19.9% and achieved a cash position of $4.7 million. Numinus managed 22 clinical trials and provided 19,961 client appointments in its wellness clinics. The company's focus on cost containment efforts resulted in a monthly cash burn rate of less than $1 million. Revenue declined due to a contraction in scheduled appointments at wellness clinics, but gross margin increased by 660 basis points. The company continues to focus on profitability and sustainability, with a total cash balance of $4.7 million and working capital of $4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.39%
Tags
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) to release Q1 2024 financial results on January 15, 2024, with a focus on psychedelic-assisted therapies. Investors and analysts can participate in the conference call and webcast to review the Company's performance and recent initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.95%
Tags
conferences earnings
Numinus Wellness Inc.

OTC:NUMIF

NUMIF Rankings

NUMIF Stock Data

23.62M
258.18M
3.9%
2.73%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver